Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Completed · Phase 2

Conditions studied: Sarcoma, Soft Tissue

In brief

The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.

Key facts

Study ID

NCT00189137

Run by

University of Michigan Rogel Cancer Center

People needed

84

Starts

2004-08-01

Expected to finish

2015-10-01

Last updated by the study team

2015-12-07

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• no evidence of metastasis
• soft tissue sarcoma
• intermediate or high histologic grade
• greater than 5 cm
• Zubrod performance status 1 or better
• age 10 or older

You may not qualify if…

• clear cell, alveolar soft part, Ewing's rhabdosarcoma, undifferentiated small cell or Kaposi's
• prior chemotherapy
• nephrectomy
• active unstable angina pectoris
• concurrent therapy

Where it is running

• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.